Ambagon Therapeutics

AmbAgon Therapeutics is a developer of molecular cancer therapies. The company focuses on researching small molecules that enhance tumor suppressor proteins. AmbAgon Therapeutics was founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin. Our team is developing a new class of drugs that can modulate previously untreatable targets and impact currently accessible targets in novel ways. These small molecule stabilizers of 14-3-3 protein complexes address significant unmet needs in critical therapeutic areas such as cancer, metabolic disorders, neurodegenerative diseases, and infectious diseases.